DBD DIEBOLD NIXDORF, Inc Insider Trading

10% Owner Millstreet Capital sells 100,000 DBD shares for $8.5M at $84.80; retains 4.10M shares

Millstreet Capital Management LLC, a 10% owner, executed an open-market sale of 100,000 shares (100.0K shares) at $84.80 on 2026-06-26, reducing its position from 4.20M shares to 4.10M shares—a -2.4% decrease. The sale occurred against a backdrop of strong near-term stock performance: DBD has gained 4.8% over the past 30 days and 9.5% over 90 days, trading at $85.02 (within 4.5% of its 52-week high of $89.05). Notably, this sale is part of a recent rapid-trading pattern at DBD: Millstreet executed five separate sells between June 8–15, 2026, all within a compressed one-week window, with outcome measurements not yet available for timing evaluation. Across Millstreet's broader cross-ticker insider history, prior sells have been poorly timed: 15 prior sells showed an average 90-day return of +11.0%, meaning the stock rose after the insider sold, with a 14.29% well-timed rate—below a neutral threshold. The company's fundamentals show modest growth (revenue +1.5% YoY, latest quarterly revenue $891.8M) against a P/E of 27.25, leaving DBD trading at elevated valuation relative to fundamentals.

10% Owner Millstreet Capital sold 231,464 shares for $19.4M at DBD; 5 sells in 14 days, reducing stake to 4.20M shares

Millstreet Capital Management, holding 4.20M shares post-transaction, executed 2 separate sales on consecutive days (June 24–25, 2026) totaling 231,464 shares for $19,434,340.12 at blended average price $83.96. This -5.2% reduction follows a sequence of 5 prior sales at DBD within a 14-day window (June 8–15), establishing a clear pattern of systematic stake reduction in a compressed timeframe. The stock price has appreciated 8.9% over 30 days and 13.3% over 90 days from transaction date, and currently trades at $84.98, near the 52-week high of $89.05. Against Millstreet's cross-ticker track record of 15 prior sells with 14.29% well-timed rate (suggesting generally poor timing outcomes at the 90-day horizon, with average +11.0% 90-day return), the rapid succession of DBD sales warrants scrutiny of whether they represent confidence-driven reduction, liquidity needs, or portfolio rebalancing.

10% owner Millstreet Capital sells 161,440 DBD shares in two transactions for $13,260,296.33, reducing holdings by 3.5%

Millstreet Capital Management LLC, a 10% owner of Diebold Nixdorf, executed 2 separate sales totaling 161,440 shares for $13,260,296.33 at an average blended price of $82.14, reducing its post-transaction stake to 4,435,896 shares from 4,597,336 shares. The stock currently trades at $82.16, essentially flat to the sale prices, while the company's P/E of 26.33 and modest 1.5% annual revenue growth suggest a mature valuation. Historically, this insider's prior trades at DBD show mixed timing: 3 of 5 recent sells resulted in negative 90-day returns (well-timed), while 2 generated positive 90-day returns, indicating the insider has occasionally sold before declines but without consistent precision. The cross-ticker track record shows a 40.00% well-timed rate with an average 90-day return of +6.8% after sells, meaning this insider's sells have more often been followed by stock appreciation across other holdings.

Millstreet Capital (10% owner) sold 18,768 shares at avg $82.08 for $1.5M; retains 4.60M shares post-transaction.

Millstreet Capital Management LLC, a 10% owner, executed two separate sales totaling 18,768 shares for $1,540,490.60 on 2026-06-10 and 2026-06-11 at a blended average price of $82.08. The transaction represents a -0.4% reduction in holdings, leaving the filer with 4,597,336 shares. The sales occurred when DBD was trading near recent highs—the current price of $81.68 is -8.3% from the 52-week high of $89.05—and the stock has gained +13.4% over the prior 30 days and +12.7% over the prior 90 days. At the same ticker, Millstreet's prior five trades show mixed timing outcomes: three of five prior sales were well-timed at the 90-day mark, though recent April 2026 sales showed negative 30-day and 90-day returns of -17.8% and -3.7%, respectively. With a P/E of 26.18 and modest annual revenue growth of +1.5%, the fundamental backdrop is unexceptional relative to the valuation.

10% owner Millstreet Capital sold 88,334 shares of DBD at $82.99 on 2026-06-08 for $7,330,988.83; stock now $80.79.

Millstreet Capital Management LLC, a 10% owner, sold 88,334 shares at $82.99, reducing holdings from 4,704,438 to 4,616,104 shares. The sale price is -9.3% from the 52-week high of $89.05. At this same ticker, Millstreet's prior 5 trades at DBD show mixed post-sale returns: 3 of 5 prior sells achieved negative 90-day returns, indicating the insider has been somewhat successful at timing exits downward. However, the cross-ticker track record shows an average 90-day return of +6.8% after sells, and a well-timed rate of 40.00%, suggesting inconsistent execution across different holdings. DBD's fundamentals show Revenue of $891,800,000.00 with modest Net income of $5,000,000.00 and Annual revenue growth of only +1.5%, paired with a P/E of 25.89 on a $2,797,627,789.68 market cap.

Diebold Nixdorf CEO Octavio Marquez buys 1,250 shares for $99,333.82; cluster buy with 2 other insiders in 14 days

Octavio Marquez, President and CEO, executed 2 separate purchases totaling 1,250 shares for $99,333.82 at a blended average price of $79.47 on 2026-05-26 and 2026-05-27. This filing joins a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting broader management alignment around current valuations. Marquez's same-ticker history at DBD shows 3 of 5 prior buys were well-timed at the 90-day mark (with positive subsequent returns), establishing a meaningful pattern of transaction timing at this specific company. The current stock price of $78.03 is 12.4% below the 52-week high and down 5.2% over 30 days, providing context for the timing and scale of this $99.3K acquisition by the chief executive.

DBD CFO Thomas Timko buys 672 shares at $74.36 ($50.0K) as stock sits -16.6% from 52-week high

Thomas S Timko, EVP and CFO of Diebold Nixdorf, purchased 672 shares of DBD at $74.36 on 2026-05-22 for a total of $49,969.92, bringing his post-transaction holdings to 75,480 shares. The purchase comes as DBD trades -16.6% from its 52-week high and has declined -11.8% over the past 30 days and -8.5% over the past 90 days. His two prior open-market purchases at DBD — on 2024-11-12 and 2024-08-09 — each produced positive returns at the 90-day mark (+8.2% and +11.2% respectively), giving him a 2 of 2 well-timed record at this ticker. His cross-ticker track record also reflects 2 prior buys with an avg 90d return of +9.7% and a 90d win rate of 100.00%.

Diebold Nixdorf CRO Jonathan Myers purchased 1,360 shares at $73.41; stock down 16.6% from 52-week high

Jonathan Myers, EVP and Chief Revenue Officer of Diebold Nixdorf, purchased 1,360 shares at $73.41 on 2026-05-22, increasing his holdings from 44,266 shares to 45,626 shares. The transaction occurred in a context where the stock is trading at $74.30, down 16.6% from its 52-week high of $89.05 and down 11.8% over the preceding 30 days. Against this backdrop of recent weakness, a revenue officer's purchase of modest size (1,360 shares, valued at $99,837.60) in his own company is worth noting, though the stock's P/E of 23.81 and the company's minimal profitability of $5.0M on $891.8M in revenue warrant close scrutiny regarding the fundamental drivers of shareholder value.

10% owner Millstreet Capital sells 112,305 shares over 2 days for $9,554,387.85; stock at 52-week high.

Millstreet Capital Management LLC executed two separate sales totaling 112,305 shares for $9,554,387.85 at prices of $85.43 and $84.77 on April 15–16, 2026, reducing holdings by 2.3% to 4,704,438 shares. The sales occurred as DBD trades at $88.77, matching its 52-week high after a +24.2% 30-day rally and +27.0% 90-day gain. Reviewing Millstreet's prior DBD sales, 0 of 4 measurable trades were well-timed at the 90-day mark (all showed positive 90-day returns, meaning stock rose after each sale). At the cross-ticker level, the insider's prior sells averaged +0.2% 30-day return and +11.0% 90-day return with a 14.29% well-timed rate. The sale size and timing relative to recent momentum merit monitoring, but the persistent pattern of post-sale price appreciation at this ticker suggests discretionary positioning rather than a material adverse-information signal.

10% owner Millstreet Capital sold 399,929 shares of DBD at $82.42 on 2026-04-08 for $32,960,468.48, reducing stake to 4,816,743 shares

Millstreet Capital Management LLC, holding approximately 10% of Diebold Nixdorf, executed a substantial open-market sale of 399,929 shares (399.9K shares) at $82.42 on 2026-04-08, yielding $32,960,468.48 ($33.0M) and reducing the stake by -7.7% to 4,816,743 shares (4.82M shares). The sale occurred near the stock's 52-week high of $84.78 and on the heels of strong momentum: +12.7% over 30 days and +25.8% over 90 days. Examining the insider's prior trading pattern at DBD—5 previous sales at this ticker—reveals a consistent pattern: 0 of 4 measurable prior sells proved well-timed at the 90-day horizon (all produced positive 90-day returns ranging from +7.1% to +12.8%), meaning the stock rallied after each prior sale. This current transaction, executed after sustained stock appreciation and near the 52-week peak, may follow the same pattern of selling into strength rather than selling before declines. The company's modest fundamentals (P/E of 18.43, +1.5% annual revenue growth, $41.1M net income on $945.2M revenue) offer limited fundamental catalyst for outsized upside, though present no immediate red flag.